论文部分内容阅读
目的:评价头孢他啶与左氧氟沙星联用对心力衰竭(心衰)伴肺部感染患者的疗效及其对炎症因子及脑钠肽水平的影响。方法:选取2015年8月—2017年2月期间收治的心衰伴肺部感染患者84例临床资料,将其随机分为对照组与治疗组(每组42例);对照组患者给予左氧氟沙星注射液治疗,治疗组患者在对照组治疗基础上加用注射用头孢他啶治疗,比较两组患者治疗后的心功能相关指标的改善情况,以及血浆炎症因子和脑钠肽水平的影响和病原菌的清除率。结果:治疗组患者治疗后心功能相关指标如左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)均优于对照组(P<0.05),血浆炎症因子如白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)与脑钠肽(BNP)值均低于对照组(P<0.05),病原菌清除率高于对照组(P<0.05)。结论:头孢他啶与左氧氟沙星联用治疗心衰伴肺部感染患者,能有效降低炎症因子及脑钠肽水平,改善了心功能相关指标并提高了病原菌清除率。
Objective: To evaluate the efficacy of ceftazidime combined with levofloxacin in the treatment of patients with heart failure and pulmonary infection and its effect on inflammatory factors and brain natriuretic peptide. Methods: Eighty-four patients with heart failure and pulmonary infection admitted from August 2015 to February 2017 were selected and randomly divided into control group and treatment group (42 cases in each group). Patients in the control group were given levofloxacin injection Fluid treatment, treatment group patients in the control group based on the treatment plus injection of ceftazidime treatment, two groups of patients after treatment to compare the improvement of cardiac function indicators, as well as the impact of plasma inflammatory factors and brain natriuretic peptide levels and the clearance of pathogens . Results: After treatment, LVESD, LVEDD and LVEF in treatment group were significantly higher than those in control group (P <0.05). Plasma levels of plasma The inflammatory cytokines such as IL-6, TNF-α and BNP were lower than those of the control group (P <0.05), and the clearance rate of pathogenic bacteria was higher than that of the control group (P <0.05). Conclusion: The combination of ceftazidime and levofloxacin in patients with heart failure and pulmonary infection can effectively reduce the levels of inflammatory cytokines and brain natriuretic peptide, improve cardiac function-related indicators and increase the clearance rate of pathogens.